COFCO TECH(000930)2025-04-25 10:25Financial Performance - The company's operating revenue for Q1 2025 was ¥4,385,440,510.90, a decrease of 7.31% compared to ¥4,731,528,010.13 in the same period last year[5] - Net profit attributable to shareholders was ¥40,531,495.76, representing a significant increase of 63.17% from ¥24,840,311.23 year-on-year[5] - Net profit for the current period is CNY 41,783,602.69, an increase of 69.59% compared to CNY 24,640,657.00 in the previous period[17] - The company reported a total profit of CNY 58,260,380.33, up 14.44% from CNY 50,993,167.99 in the previous period[17] - Basic and diluted earnings per share increased to CNY 0.0218 from CNY 0.0134 in the previous period[17] Cash Flow - The net cash flow from operating activities improved to -¥256,367,445.32, an 81.88% increase compared to -¥1,414,584,529.72 in the previous year[5] - Cash inflow from operating activities totaled CNY 5,182,926,501.75, down from CNY 5,929,009,821.95 in the previous period[19] - Net cash flow from financing activities was 608,948,544.87, a decrease from 1,504,712,206.77 in the previous period[21] - Total cash and cash equivalents at the end of the period amounted to 1,676,139,351.71, down from 1,797,191,625.92 at the beginning of the period[21] - The net increase in cash and cash equivalents was -121,052,274.21, indicating a decline compared to -214,772,391.25 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥17,822,695,480.37, reflecting a 2.85% increase from the previous year[5] - Current assets amounted to CNY 7,333,681,599.88, up from CNY 6,810,032,146.29 at the start of the period[13] - Total liabilities increased to CNY 6,848,983,135.52 from CNY 6,412,706,650.24[14] - The company's total equity stood at CNY 10,973,712,344.85, reflecting a slight increase from the previous period[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 116,526[10] - The largest shareholder, COFCO Bio, holds 47.58% of the shares, totaling 883,233,262 shares[10] - The total equity attributable to shareholders increased slightly by 0.53% to ¥10,573,866,268.36[5] Research and Development - Research and development expenses rose by 76.09% to ¥53,907,076.70, indicating increased investment in innovation[8] - Research and development expenses increased to CNY 53,907,076.70, up 76.00% from CNY 30,614,055.85 in the previous period[16] Investment Income - The company reported a significant increase in investment income, which reached ¥32,100,905.52, a 470.52% rise compared to -¥8,663,739.90 in the previous year[8]